Pliant Therapeutics, Inc.

NASDAQ:PLRX

Biotechnology

Healthcare
$0.81 -3.39%

-$0.04 today

Market cap
$50.14M
Beta
1.21
P/E (TTM)
-0.6
EPS (TTM)
-$1.83
52W Low $1.09High $1.95

Volume 0.15M

Average 0.49M

Returns on capital

Pliant Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-82.4%

avg 297.0%

ROIC

-71.4%

avg -96.6%

ROA

-66.3%

avg -67.2%

Analysis

ROA is currently the strongest return metric at -66.3% versus its period average of -67.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Bernard Coulie

President, Chief Executive Officer & DirectorUSD 938.9K600<0.01%

Keith Lamont Cummings

Chief Financial OfficerUSD 820.2K490<0.01%

Minnie Kuo

Chief Operating OfficerUSD 774.47K450<0.01%

Dean Sheppard

Scientific Founder & Member of Scientific Advisory Board————

Hal Chapman

Scientific Founder & Member of Scientific Advisory Board————

Tim Machajewski

Senior VP & Head of Research————

Monica Sandberg

Vice President, Regulatory & Compliance————

Bill DeGrado

Scientific Founder————

Christopher S. Keenan

Vice President of Investor Relations & Corporate Communications————

Delphine Imbert

Chief Technical Officer————

Lily Cheung

Chief Human Resources Officer—530<0.01%

Daniel Park

Senior Vice President of Development Operations————

Scott Peters

Senior Vice President of Finance————

Rik Derynck

Scientific Founder & Member of Scientific Advisory Board————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Apr 17, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

4

$163,619.84

Net Transaction Value

−$163,619.84

Net selling

Most Active

Cummings Keith Lamont

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jan 20, 26

Cummings Keith Lamont

Direct

Sell$30.7K
Jan 20, 26

Cheung Lily

Direct

Sell$9.6K
Jan 20, 26

Coulie Bernard

Direct

Sell$114.4K
Jan 20, 26

Kuo Minnie

Direct

Sell$8.9K

Summary

Insiders reported 0 buys worth $0.00 and 4 sells worth $163,619.84 over the last 12 months. That adds up to net selling of $163,619.84. Cummings Keith Lamont was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Pliant Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about PLRX's management, answered from reported figures.

Who manages PLRX?

Pliant Therapeutics, Inc. (PLRX) lists 14 active executives. The top listed executive is Bernard Coulie, President, Chief Executive Officer & Director.

Are PLRX insiders buying or selling?

Recent insider activity shows net selling of $22.94M.